Melanie Leitner, PhD
Founder of Accelerating NeuroVentures
Melanie is an internationally recognized thought leader in Amyotrophic Lateral Sclerosis (ALS), and an expert in the incentivized prize space. Melanie advises companies, foundations, and investors interested in translating neuroscience discoveries into breakthroughs for patients. She has spent her career in government, academia, and both the non-profit and for-profit sectors, breaking down barriers and promoting cross-disciplinary collaboration.
Before founding Accelerating NeuroVentures, Melanie was an Associate Director at Biogen, where she served as a key member of the ALS clinical development and program teams. She was a cross functional-player on both the scientific and business development teams where she was responsible for vetting scientific strategy, collaborations, and acquisitions. Prior to that, she was the CSO of Prize4Life, where she developed and managed the programmatic initiatives of the organization designed to fill translational gaps in ALS research and drug development.
Melanie earned a Ph.D. in Neuroscience from Washington University in St.Louis. She holds a SBc in Neural Sciences from Brown University.